Antithrombotic Therapy in Atrial Fibrillation : – Evaluation and Positioning of New Oral Anticoagulant Agents –
スポンサーリンク
概要
- 論文の詳細を見る
Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for stroke. For more than 60 years, warfarin has been the only approved anticoagulant for prevention of stroke in patients with AF. Although highly effective, it has many limitations that make its use difficult. Therefore, several novel anticoagulants are under development to overcome the limitations of warfarin, and some of these have entered phase III clinical trials. Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery. It has also been approved in the United States and Japan for the prevention of stroke and systemic embolism in patients with nonvalvular AF. In this review, the mechanism of action and pharmacological properties of new anticoagulants are described in detail, and the correct use of dabigatran in clinical practice is discussed. (Circ J 2011; 75: 1539-1547)
論文 | ランダム
- 総合討論 (日本農業法学会二〇〇九年度年次大会 シンポジウム「地域における農地管理と改正農地法--長野県における経験と展望」)
- 憲法二五条の福祉と国民の生活保障 (特集 憲法と国民生活)
- 最近の平城京発掘調査から--左京五条四坊の調査 (特集 平城遷都1300年)
- 『圓理規矩算法』規形綴術の第三, 四, 五條と第七, 九條について
- DNAマイクロアレイによる海域微生物叢のメタゲノム解析の試み